<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99173">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01930058</url>
  </required_header>
  <id_info>
    <org_study_id>8876-003</org_study_id>
    <secondary_id>2013-002566-39</secondary_id>
    <nct_id>NCT01930058</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-8876 in Hepatitis C Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Moldova: Health Ministry of Republic of Moldova</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This adaptive design study will evaluate the safety, pharmacokinetics, and effect on
      hepatitis C virus (HCV) RNA levels of multiple doses of MK-8876 in participants with HCV
      infection. The study will consist of 4 parts evaluating participants infected with specific
      hepatitis C virus genotypes and up to 10 panels allowing for additional participants to
      enroll in each panel as specified in the study analysis. The hypothesis evaluated in the
      study is that a ≥2.5 log IU/mL reduction in HCV RNA from Baseline will accompany multiple
      dose administration of MK-8876 in participants with HCV infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean maximum change from baseline in HCV RNA</measure>
    <time_frame>Baseline and up to Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steady state mean area under the MK-8876 plasma concentration versus time curve (AUC0-24 hr)</measure>
    <time_frame>Before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours after dosing on Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state mean MK-8876 plasma concentration (C24 hr)</measure>
    <time_frame>24 hours after dosing on Day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>HCV genotype GT3 participants (Panel A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8876 200 mg oral once daily (qd) for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV genotype GT3 participants (Panel B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8876 ≤800 mg oral qd for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV genotype GT3 participants (Panel C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8876 ≤800 mg oral qd for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV genotype GT3 participants (Panel D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8876 ≤800 mg oral qd for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV genotype GT1a participants (Panel E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8876 ≤800 mg oral qd for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV genotype GT1a participants (Panel F)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8876 ≤800 mg oral qd for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV genotype GT1b participants (Panel G)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8876 ≤800 mg oral qd for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV genotype GT1b participants (Panel H)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8876 ≤800 mg oral qd for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV genotype GT2 participants (Panel I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8876 ≤800 mg oral qd for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV genotype GT2 participants (Panel J)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8876 ≤800 mg oral qd for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8876 200 mg or ≤800 mg</intervention_name>
    <arm_group_label>HCV genotype GT3 participants (Panel A)</arm_group_label>
    <arm_group_label>HCV genotype GT3 participants (Panel B)</arm_group_label>
    <arm_group_label>HCV genotype GT3 participants (Panel C)</arm_group_label>
    <arm_group_label>HCV genotype GT3 participants (Panel D)</arm_group_label>
    <arm_group_label>HCV genotype GT1a participants (Panel E)</arm_group_label>
    <arm_group_label>HCV genotype GT1a participants (Panel F)</arm_group_label>
    <arm_group_label>HCV genotype GT1b participants (Panel G)</arm_group_label>
    <arm_group_label>HCV genotype GT1b participants (Panel H)</arm_group_label>
    <arm_group_label>HCV genotype GT2 participants (Panel I)</arm_group_label>
    <arm_group_label>HCV genotype GT2 participants (Panel J)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, or female of non-childbearing potential. Non-childbearing potential is defined
             as postmenopausal without menses for ≥1 year or after medically documented
             hysterectomy, oophorectomy, or tubal ligation

          -  Participants with female partner of childbearing potential must use a medically
             acceptable method of contraception through 90 days after the last dose of study drug

          -  Males should use a condom and their partner of childbearing potential must use
             hormonal contraception, intrauterine device, diaphragm, cervical cap, or female
             condom

          -  Body mass index between 18 and 37 kg/m^2

          -  Clinical diagnosis of chronic HCV infection defined by positive serology for HCV for
             ≥6 months

          -  Agrees to follow the smoking and other trial restrictions

        Exclusion Criteria:

          -  Mentally or legally institutionalized or incapacitated, has significant emotional
             problems at study start or has clinically significant psychiatric disorder of the
             last 5 years

          -  History of clinically significant endocrine, gastrointestinal (except HCV infection),
             cardiovascular, hematological, hepatic, immunological, renal, respiratory, or
             genitourinary abnormalities or diseases

          -  History of stroke, chronic seizures, or major neurological disorder

          -  History of cancer (except adequately treated non-melanomatous skin carcinoma,
             carcinoma in situ of the cervix, or other malignancies which have been successfully
             treated for ≥10 years

          -  History of significant multiple and/or severe allergies or has had an anaphylactic
             reaction or significant intolerability to drugs or food

          -  History of clinically significant hepatic disease, Gilbert's disease, biliary tract
             disease, or human immunodeficiency virus

          -  Had major surgery or donated or lost &gt;1 unit of blood within 4 weeks before the study

          -  Participated in another investigational trial within 4 weeks before the study

          -  Is unable to refrain from or anticipates the use of any medication from 2 weeks
             before the study and throughout the study

          -  Consumes &gt;2 glasses of alcoholic beverages per day

          -  Consumes &gt;6 servings (1 serving is ~120 mg caffeine) of coffee, tea, cola, energy
             drinks, or other caffeinated beverages per day

          -  Regular user of any illicit drugs or history of drug abuse within 12 months of the
             study

          -  Evidence or history of chronic hepatitis not caused by HCV (except acute
             non-HCV-related hepatitis that resolved &gt;6 months before the study)

          -  Previous treatment with another HCV non-nucleoside inhibitor (previous use of other
             HCV investigational therapies or marketed compounds is permitted if treatment ended
             ≥3 months before the study)

          -  Clinical or laboratory evidence of advanced or decompensated liver disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>August 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
